LAS VEGAS, June 5, 2025 /PRNewswire/ -- DelveInsight's Friedreich's Ataxia Market Insights report includes a comprehensive understanding of current treatment practices, Friedreich's ataxia emerging ...

Friedreich’s ataxia patients met with staff from Tallaght Hospital last week who explained the limitations in the current ...

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company ...

IntraBio is on a roll with its expansion plans for chemically altered amino acid, Aqneursa. | IntraBio's streak of success in the rare neurological category continues, as the drugmaker racks up a ...

Patients with Friedreich's Ataxia have called for change following their successful campaign for the HSE to fund the drug Skyclarys, saying that other rare disease patients should not have to "beg" ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The trial will evaluate VO659, an antisense ...

Please provide your email address to receive an email when new articles are posted on . Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years ...

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical ...

It emerged this week the HSE expects to have reimbursement arrangements in place by October 1 for Skyclarys ...

A study investigated the origin of ataxia in the brain of patients with stroke. A significant number of the stroke lesions in the patients were located outside the cerebellum. A new study by the ...